In silico screening for identification of pyrrolidine derivatives dipeptidyl peptidase-IV inhibitors using COMFA, CoMSIA, HQSAR and docking studies. [PDF]
In Silico Pharmacol, 2017 Sharma MC, Jain S, Sharma R.
europepmc +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 5091-5100, June 2026.ABSTRACT Aims Studies evaluating automated insulin delivery (AID) in type 2 diabetes are limited in number and often conducted in small cohorts. We aimed to summarize efficacy and safety data through a systematic review and meta‐analysis. Materials and Methods We searched MEDLINE, PubMed, Web of Science, and CENTRAL databases and performed hand ...
Sergio Di Molfetta +7 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 5217-5228, June 2026.ABSTRACT Aims There is ongoing uncertainty about whether initiating sodium–glucose co‐transporter 2 inhibitor (SGLT‐2i) therapy in individuals with type 2 diabetes (T2D) who have elevated baseline HbA1c levels may lead to an additive or potentially synergistic increase in the risk of diabetic ketoacidosis (DKA). This systematic review and meta‐analysis
Samuel Seidu +3 more
wiley +1 more source
Safety and Efficiency of Dipeptidyl Peptidase IV Inhibitors in Patients with Diabetic Kidney Disease: A Systematic Review and Meta-Analysis. [PDF]
Curr Ther Res Clin ExpTuersun A, Mohetaer M, Hou G, Cheng G.
europepmc +1 more source
In vitro screening for protein tyrosine phosphatase 1B and dipeptidyl peptidase IV inhibitors from selected Nigerian medicinal plants. [PDF]
J Intercult Ethnopharmacol, 2017 Saidu Y +5 more
europepmc +1 more source
Journal of Evaluation in Clinical Practice, Volume 32, Issue 4, June 2026.ABSTRACT Introduction Cardiovascular and cerebrovascular diseases are projected to expand in the coming decades as the main cause of death. This study outlines the escalating burden of cardiovascular diseases in low‐ and middle‐income countries (LMICs), particularly in Latin America (LA), which is expected to surpass that of other high‐population ...
Renato de Carvalho Barros +22 more
wiley +1 more source
Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition
Molecular Oncology, Volume 20, Issue 5, Page 1347-1363, May 2026.We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li +10 more
wiley +1 more source
Efficacy and Safety of the Utilization of Dipeptidyl Peptidase IV Inhibitors in Diabetic Patients with Chronic Kidney Disease: A Meta-Analysis of Randomized Clinical Trials. [PDF]
Diabetes Metab Syndr ObesMahzari MM +6 more
europepmc +1 more source
Overview of molecular signatures of senescence and associated resources: pros and cons
FEBS Open Bio, Volume 16, Issue 5, Page 821-836, May 2026.Cells can enter a stress response state termed cellular senescence that is involved in various diseases and aging. Detecting these cells is challenging due to the lack of universal biomarkers. This review presents the current state of senescence identification, from biomarkers to molecular signatures, compares tools and approaches, and highlights ...
Orestis A. Ntintas +6 more
wiley +1 more source
How does type 2 diabetes modify the risk of Alzheimer's disease?
Alzheimer's &Dementia, Volume 22, Issue 5, May 2026.Abstract Type 2 diabetes (T2D) and Alzheimer's disease (AD) are both increasing exponentially worldwide. T2D has also been identified as one of 14 modifiable risk factors for dementia, but the mechanism is unknown. T2D could promote dementia via vascular or AD neuropathological changes, and mechanistic hypotheses include central insulin resistance and ...
G. T. Sutherland +7 more
wiley +1 more source